Our Pipeline
KLN-1010
Multiple Myeloma
CD19/BCMA biCAR
Oncology & Autoimmune
Undisclosed
Oncology
KLN-1010
Multiple Myeloma
CD19/BCMA biCAR Oncology/I&I
Undisclosed
Oncology
Our Clinical Trial
inMMyCAR is our Phase 1 clinical trial for KLN-1010 and is open and enrolling patients. This first in-human study is designed to assess the safety and preliminary efficacy of a single dose of KLN-1010 in patients with refractory multiple myeloma. Additional information and study site information can be found here and on clinicaltrials.gov (NCT07075185).
Expanded Access Policy:
Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial.
Kelonia Therapeutics does not currently offer expanded access to any of our investigational products.
We understand that for patients with serious diseases such as cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trial programs provides the best path to meet our goal of providing therapeutics to patients with cancer.
We may reevaluate the status of our Expanded Access Policy as development of our investigational products progresses. Kelonia Therapeutics reserves the right to revise this Expanded Access Policy at any time.
We encourage you to speak with your physician about options that may be right for you.